A circulating tumor cell-RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer

Yu Jen Jan, Junhee Yoon, Jie Fu Chen, Pai Chi Teng, Nu Yao, Shirley Cheng, Amber Lozano, Gina C.Y. Chu, Howard Chung, Yi Tsung Lu, Pin Jung Chen, Jasmine J. Wang, Yi Te Lee, Minhyung Kim, Yazhen Zhu, Beatrice S. Knudsen, Felix Y. Feng, Isla P. Garraway, Allen C Gao, Leland W.K. ChungMichael R. Freeman, Sungyong You, Hsian Rong Tseng, Edwin M. Posadas

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Rationale: Our objective was to develop a circulating tumor cell (CTC)-RNA assay for characterizing clinically relevant RNA signatures for the assessment of androgen receptor signaling inhibitor (ARSI) sensitivity in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: We developed the NanoVelcro CTC-RNA assay by combining the Thermoresponsive (TR)-NanoVelcro CTC purification system with the NanoString nCounter platform for cellular purification and RNA analysis. Based on the well-validated, tissue-based Prostate Cancer Classification System (PCS), we focus on the most aggressive and ARSI-resistant PCS subtype, i.e., PCS1, for CTC analysis. We applied a rigorous bioinformatic process to develop the CTC-PCS1 panel that consists of prostate cancer (PCa) CTC-specific RNA signature with minimal expression in background white blood cells (WBCs). We validated the NanoVelcro CTC-RNA assay and the CTC-PCS1 panel with well-characterized PCa cell lines to demonstrate the sensitivity and dynamic range of the assay, as well as the specificity of the PCS1 Z score (the likelihood estimate of the PCS1 subtype) for identifying PCS1 subtype and ARSI resistance. We then selected 31 blood samples from 23 PCa patients receiving ARSIs to test in our assay. The PCS1 Z scores of each sample were computed and compared with ARSI treatment sensitivity. Results: The validation studies using PCa cell line samples showed that the NanoVelcro CTC-RNA assay can detect the RNA transcripts in the CTC-PCS1 panel with high sensitivity and linearity in the dynamic range of 5-100 cells. We also showed that the genes in CTC-PCS1 panel are highly expressed in PCa cell lines and lowly expressed in background WBCs. Using the artificial CTC samples simulating the blood sample conditions, we further demonstrated that the CTC-PCS1 panel is highly specific in identifying PCS1-like samples, and the high PCS1 Z score is associated with ARSI resistance samples. In patient bloods, ARSI-resistant samples (ARSI-R, n=14) had significantly higher PCS1 Z scores as compared with ARSI-sensitive samples (ARSI-S, n=17) (Rank-sum test, P=0.003). In the analysis of 8 patients who were initially sensitive to ARSI (ARSI-S) and later developed resistance (ARSI-R), we found that the PCS1 Z score increased from the time of ARSI-S to the time of ARSI-R (Pairwise T-test, P=0.016). Conclusions: Using our new methodology, we developed a first-in-class CTC-RNA assay and demonstrated the feasibility of transforming clinically-relevant tissue-based RNA profiling such as PCS into CTC tests. This approach allows for detecting RNA expression relevant to clinical drug resistance in a non-invasive fashion, which can facilitate patient-specific treatment selection and early detection of drug resistance, a goal in precision oncology.

Original languageEnglish (US)
Pages (from-to)2812-2826
Number of pages15
JournalTheranostics
Volume9
Issue number10
DOIs
StatePublished - Jan 1 2019

Keywords

  • Androgen receptor signaling inhibitors
  • Cancer RNA profiling
  • Circulating tumor cell
  • Metastatic castration-resistant prostate cancer

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Fingerprint Dive into the research topics of 'A circulating tumor cell-RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Jan, Y. J., Yoon, J., Chen, J. F., Teng, P. C., Yao, N., Cheng, S., Lozano, A., Chu, G. C. Y., Chung, H., Lu, Y. T., Chen, P. J., Wang, J. J., Lee, Y. T., Kim, M., Zhu, Y., Knudsen, B. S., Feng, F. Y., Garraway, I. P., Gao, A. C., ... Posadas, E. M. (2019). A circulating tumor cell-RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer. Theranostics, 9(10), 2812-2826. https://doi.org/10.7150/thno.34485